Abbott Laboratories (Pakistan) Limited

ABOT

PK0025701019

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
577.6 ^PKR	+0.50%		+5.41%	+25.51%

Mar. 30	Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Abbott Laboratories Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2019

April 23, 2019 at 07:04 am EDT

Abbott Laboratories Pakistan Limited announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced total revenue was PKR 7,215.799 million compared to PKR 6,332.524 million a year ago. Net income was PKR 327.669 million compared to PKR 620.232 million a year ago. Basic earnings per share was PKR 3.35 compared to PKR 6.34 a year ago.

Latest news about Abbott Laboratories (Pakistan) Limited

Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
Abbott Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-27	CI
Abbott Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-01	CI
Abbott Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-30	CI
Abbott Laboratories Announces Board Changes	22-08-25	CI
Abbott Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-27	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-27	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-23	CI
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-26	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-28	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-28	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-29	CI
Abbott Laboratories Proposes Cash Dividend for the Financial Year Ended December 31, 2019	20-03-18	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-02	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-10-17	CI
Abbott Laboratories Limited Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-16	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2019	19-04-23	CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2018	19-02-21	CI
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended Sept. 30, 2018	18-10-19	CI
Abbott Laboratories Limited Announces Interim Cash Dividend for the Year Ending December 31, 2018	18-09-24	CI

Chart Abbott Laboratories (Pakistan) Limited

Duration

Period

Chart Abbott Laboratories (Pakistan) Limited

More charts

Company Profile

Abbott Laboratories Pakistan Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, womenâs health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Companyâs easy-to-use test strips require only tiny blood samples while its meters provide results and reports.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBOTT LABORATORIES (PAKISTAN) LIMITED	+25.51%	203M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B